Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT01290718
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
Phase 3
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT01290094
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Phase 3
Terminated
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1418
- Registration Number
- NCT01287741
- Locations
- 🇨🇦
Humber River Hospital, Toronto, Ontario, Canada
🇺🇸UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States
🇵🇱Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01287754
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01286753
Safety Extension Study of TRO19622 in ALS
Phase 2
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: TRO19622
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT01285583
- Locations
- 🇫🇷
CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement, Lille, France
🇫🇷HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel, Bron Cedex, France
🇫🇷Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Phase 4
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT01283971
An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 79
- Registration Number
- NCT01283399
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
Phase 4
Terminated
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT01283386
- Locations
- 🇷🇺
City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation
🇷🇺Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation
🇷🇺The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)
Completed
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 107
- Registration Number
- NCT01283074
© Copyright 2025. All Rights Reserved by MedPath